Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind, placebo-controlled trial of PC-SOD to prevent chemotherapy-induced peripheral neuropathy
jRCT2031210466Phase 2Completed
- Sponsor
- LTT Bio-Pharma Co., Ltd.
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing PC-SOD arm with Placebo arm (2 arms). Primary endpoint: Incidence of chemotherapy-induced peripheral neuropathy. Started Jan 2022; status: completed.
02
Drugs
lecithinized superoxide dismutase
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCT2031210466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210466.